All In Biotech

Drug Trial Radar · NCT05182840

A Study to Test Whether Different Doses of BI 690517 Alone or in Combination With Empagliflozin Improve Kidney Function in People With Chronic Kidney Disease

Randomised, Double-blind, Placebo-controlled and Parallel Dose Group Trial to Investigate Efficacy and Safety of Multiple Doses of Oral BI 690517 Over 14 Weeks, Alone and in Combination With Empagliflozin, in Patients With Diabetic and Non-diabetic Chronic Kidney Disease

Last checked: Nov 19, 2026Latest source record: Oct 22, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 714 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

714

Actual

Start

Jan 11, 2022

Primary completion

Jun 19, 2023

Study completion Jul 10, 2023

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
Jan 10, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is open to adults with chronic kidney disease. People with and without type 2 diabetes can take part in this study. The purpose of this study is to find out whether a medicine called BI 690517 improves kidney function in people with chronic kidney disease when taken alone or in combination with a medicine called empagliflozin. In the first part of the study, participants take empagliflozin or placebo as tablets every day for 2 months. Placebo tablets look like empagliflozin tablets but do not contain any medicine. In the second part, participants are divided into several groups. Depending on the group, the participants then additionally take different doses of BI 690517 or placebo as tablets for 3.5 months. In this case, placebo tablets look like BI 690517 tablets but do not contain any medicine. Participants are in the study for about 6 months. During this time, they visit the study site about 12 times. Where possible, about 4 of the 12 visits can be done at the participant's home instead of the study site. The trial staff may also contact the participants by phone or video call. Participants collect urine samples at home. These samples are then analysed to assess kidney function. At the end of the trial the results are compared between the different groups. The doctors also regularly check participants' health and take note of any unwanted effects.

Conditions

  • Kidney Disease, Chronic

Interventions

  • BI 690517Drug

    Film-coated tablets

  • Placebo to BI 690517Drug

    Film-coated tablets

  • EmpagliflozinDrug

    Empagliflozin

  • Placebo to empagliflozinDrug

    Placebo to empagliflozin

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Treatment Period Baseline in Log Transformed Urine Albumin Creatinine Ratio (UACR) Measured in First Morning Void (FMV) Urine After 14 Weeks - All PatientsTime frame: The MMRM model is a longitudinal analysis and it incorporated UACR measurements from baseline (Week 6,7 or 8 of the Run-in period) and Week 6, Week 10 and Week 12-14 of Treatment period.
  2. Percent Change of FMV UACR From Baseline to Week 14 Based on Adjusted Median (95% CI) Back Transformed From MMRM Estimate - All PatientsTime frame: The MMRM model is a longitudinal analysis and it incorporated UACR measurements from baseline (Week 6,7 or 8 of the Run-in period) and Week 6, Week 10 and Week 12-14 of Treatment period.
  3. Change From Baseline to Week 14 in the Log Transformed FMV UACR - Patients With Background Therapy of Placebo Matching EmpagliflozinTime frame: The MMRM model is a longitudinal analysis and it incorporated UACR measurements from baseline (Week 6,7 or 8 of the Run-in period) and Week 6, Week 10 and Week 12-14 of Treatment period.
  4. Percent Change of FMV UACR From Baseline to Week 14 Based on Adjusted Median (95% CI) Back Transformed From MMRM Estimate - Patients With Background Therapy of Placebo Matching EmpagliflozinTime frame: The MMRM model is a longitudinal analysis and it incorporated UACR measurements from baseline (Week 6,7 or 8 of the Run-in period) and Week 6, Week 10 and Week 12-14 of Treatment period.
  5. Change From Baseline to Week 14 in the Log Transformed FMV UACR - Patients With Background Therapy of EmpagliflozinTime frame: The MMRM model is a longitudinal analysis and it incorporated UACR measurements from baseline (Week 6,7 or 8 of the Run-in period) and Week 6, Week 10 and Week 12-14 of Treatment period.
  6. Percent Change of FMV UACR From Baseline to Week 14 Based on Adjusted Median (95% CI) of MMRM Estimate - Patients With Background Therapy of EmpagliflozinTime frame: The MMRM model is a longitudinal analysis and it incorporated UACR measurements from baseline (Week 6,7 or 8 of the Run-in period) and Week 6, Week 10 and Week 12-14 of Treatment period.

Locations

203 sites in 29 countries. Site status is shown where the registry gives one.

  • Aventiv Research Inc.

    Mesa, Arizona

  • AKDHC Medical Research Services, LLC

    Phoenix, Arizona

  • Clearview Medical Research, LLC

    Canyon Country, California

  • Pacific Renal Associates

    Long Beach, California

  • Amicis Research Center

    Northridge, California

  • Valley Clinical Trials, Inc.

    Northridge, California

  • California Kidney Specialists

    San Dimas, California

  • Colorado Kidney Care

    Denver, Colorado

  • Clinical Research of Brandon LLC

    Brandon, Florida

  • Horizon Research Group

    Coral Gables, Florida

  • Elixia Fort Lauderdale, LLC

    Fort Lauderdale, Florida

  • South Florida Research Institute

    Lauderdale Lakes, Florida

  • San Marcus Research Clinic, Inc.

    Miami, Florida

  • Total Research Group, LLC

    Miami, Florida

  • Horizon Research Group, LLC

    Miami, Florida

  • West Orange Endocrinology

    Ocoee, Florida

  • Pines Care Research Center

    Pembroke Pines, Florida

  • Elixia Tampa, LLC

    Temple Terrace, Florida

  • Boise Kidney and Hypertension PLLC

    Nampa, Idaho

  • Cedar Crosse Research Center

    Chicago, Illinois

  • Kansas Nephrology Research Institute, LLC

    Wichita, Kansas

  • Aa Mrc Llc

    Flint, Michigan

  • Elite Research Center, LLC

    Flint, Michigan

  • Clinical Research Consultants, LLC

    Kansas City, Missouri

  • Forte Family Practice

    Las Vegas, Nevada

  • New Mexico Clinical Research and Osteoporosis Center, Inc.

    Albuquerque, New Mexico

  • Triad Internal Medicine

    Asheboro, North Carolina

  • Lucas Research, Inc.

    Morehead City, North Carolina

  • Diabetes & Endocrinology Associates of Stark County

    Canton, Ohio

  • Cleveland Clinic

    Cleveland, Ohio

  • Heritage Valley Medical Group

    Beaver, Pennsylvania

  • Elixia Upland, LLC

    Upland, Pennsylvania

  • Monument Health

    Rapid City, South Dakota

  • Knoxville Kidney Center PLLC

    Knoxville, Tennessee

  • Research Institute of Dallas

    Dallas, Texas

  • Academy Of Diabetes, Thyroid And Endocrine, PA

    El Paso, Texas

  • PrimeCare Medical Group

    Houston, Texas

  • P&I Clinical Research, LLC

    Lufkin, Texas

  • Simcare Medical Research, LLC

    Sugar Land, Texas

  • Providence Medical Research Center

    Spokane, Washington

Showing 40 of 203 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.